Longevity Atlas · Evidence intelligence for the longevity economy
Evidence due diligence before you bet on a longevity ingredient.
Clinical trials, PubMed literature, null results, and supplier signals — turned into citable reports for supplement brands, formulators, clinics, and investors.
Decision Briefs
A report your regulatory, formulation, or investment team can file.
Ingredient evidence dossiers, supplier shortlists, and claim-risk briefs — built on primary sources, not brand marketing. From $499.
Intelligence feed
What serious operators are reading about longevity.
Landmark science, capital flow, policy shifts, and founder signals.
The Longevity Operating System
Why, in the AI era, the scarcest asset to manage is no longer your time — but your healthspan. The five-layer system every person can run, and the evidence layer it's missing.
Read the whitepaperThe Hallmarks of Aging: An Expanding Universe
The field's foundational map — twelve hallmarks now define what aging is and where intervention is possible.
Altos Labs launched with ~$3B for cellular rejuvenation
Backed by Bezos and Yuri Milner with Nobel laureate Shinya Yamanaka — the largest private bet that aging is programmable.
Hevolution commits up to $1B/year to healthspan science
Saudi-established and now among the world's largest geroscience funders — sovereign capital is entering longevity.
Supplier intelligence
Ingredients mapped to the suppliers who carry them.
Each ingredient profile links to suppliers in our directory. Need deeper vetting? We run COA audits and sourcing matchmaking.
Modern Chinese tea drink brand using cultural packaging and retail beverage positioning.
Calm Shen WellnessClinic-adjacent Chinese medicine wellness tea line focused on calm, sleep, and digestive routines.
CHAGEEModern Chinese teahouse chain using premium whole tea leaves and global retail expansion.
Get started
Commission your first evidence brief.
For supplement brands, formulators, clinics, investors, and private clients. Starting at $499.